R.N. Supreeth: Does CDK4/6 Inhibitor-Induced Neutropenia Warrant G-CSF?
4h agoen
From the article
R.N. Supreeth, Consultant Medical Oncologist at Sri Shankara Cancer Hospital and Research Centre, shared a post on LinkedIn: “Does CDK I induced Neutropenia warrant GCSF? Does it work? When can we safely […]
Continue reading on OncoDailyYou might also wanna read
CCR study reveals how leukemia chemotherapy drug Ara-C damages neurons causing balance problems
CCR scientists led by Andre Nussenzweig have discovered why the chemotherapy drug Ara-C (used to treat blood cancers) causes movement and ba
go.nih.gov·15d ago
Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy
doi.org·1d ago
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
Nature Communications·7d ago
Germline Testing in Pediatric High-Grade Gliomas Reveals Cancer Predisposition Variants, Supporting Routine Diagnostic Integration
This retrospective study from Bambino Gesù Children's Hospital in Rome investigated the link between pediatric high-grade gliomas (PHGGs) an
cell.com·6d ago
Protein-based pan-RAS inhibitor induces tumor regression in female mice via IFNγ and CD8+ T cell-dependent tumor necrosis
doi.org·18d ago
Breast Cancer Treatment Strategies: AI ± CDK4/6 Inhibitors, Biomarkers, and ESR1 Mutations
This article appears to be a medical education piece focused on breast cancer treatment strategies, specifically discussing patients progres
mdsc.pe·15d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.